Navigation Links
Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
Date:2/3/2009

fected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation

'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
2. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
3. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
4. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
5. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
6. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
7. Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
8. Headache Specialists Convene in Boston For 50th Annual American Headache Society Meeting
9. Leading Immunologists Convene in Boston
10. Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City
11. Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientifics SpyGlass(R) Direct Visualization System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Pharma IQ, after ... successful Serialisation Countdown calendar to cover the years 2014 ... pharmaserialisation.com shows the serialisation requirements around the globe ... into force. For companies dealing with international ... but "when" they will have to comply with new ...
(Date:9/18/2014)... 2014 MiMedx Group, Inc. (NASDAQ: ... marketer of patent protected regenerative biomaterials and bioimplants ... it has entered into a distribution agreement with ... its dehydrated human amnion/chorion membrane ("dHACM") allograft products ... a private label basis. The MiMedx ...
(Date:9/18/2014)... 2014  Zacks.com announces the list of stocks featured ... Research analysts discuss the latest news and events impacting ... the blog include the Avanir Pharmaceuticals (Nasdaq: AVNR - ... Free Report ), Orexigen (Nasdaq: OREX - Free ... ) and Gilead (Nasdaq: GILD - Free Report ...
Breaking Medicine Technology:Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
(Date:9/18/2014)... It’s been just a few short weeks since ... splint to website visitors, but already the response has been ... delighted. It is perfect and I find it sooo much ... YOU FOR LISTENING!!!" Another user compared the original design ... to slip to the end of my toe. Now that ...
(Date:9/18/2014)... LAKE, Wis. (PRWEB) September 18, 2014 It ... and engage in health and wellness. Once again, Evensong ... in Spa Week by offering three services at a special ... Evensong Spa, managed by Marcus Hotels & Resorts , ... a national event encouraging Americans to embrace health and wellness ...
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... In 2003, the government ... Barrio Adentro), which it hoped would increase ... Section 6.1.3.). In 2009, it invested VEF28 ... of Pharmaceutical Elaborations (Servicio Autónomo de Elaboraciones ... at a cheaper rate than private pharmaceutical ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Qualis Health, ... has published a white paper, “Advancing Primary Care ... Health Information Technology.” , Authors Jeff Hummel, MD, ... provide guidance to organizations engaged in the work of ... health IT can bolster PCMH objectives, such as generating ...
Breaking Medicine News(10 mins):Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:Evensong Spa Celebrates Spa Week with $50 Services 2Health News:Evensong Spa Celebrates Spa Week with $50 Services 3Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2
... Reduce Stiffness for Better Health with,Innovative ,Sleep and ... FORT LAUDERDALE, Fla., Jan. 9 Contour ... people implement an,ergonomic makeover into their life for ... well being. By aligning the body, relieving,pressure points ...
... Makes Available New Daily Dosing Option for the Treatment ... and Company,(NYSE: LLY ) announced today that the ... for once daily use (2.5 mg and,5 mg), an ... dysfunction,(ED). When Cialis for once daily use is taken ...
... private equity, public offering, ... Irell represents leading clients in gaming, green tech, ... construction, LOS ANGELES, Jan. 8 Irell & Manella ... corporate deals,valued at more than $7 billion., The firm ...
... years, The Leukemia &,Lymphoma Society has organized "Team ... achieve personal goals and most of all, raised,over ... video from The Leukemia & Lymphoma Society at:, ... In Training" helps,individuals prepare for a full marathon ...
... Red Cross,announced today that J. Chris Hrouda has ... for the organization,s Biomedical Services., Hrouda will ... Each year the American Red Cross collects approximately ... million blood products to,patients at approximately 3,000 hospitals ...
... 8 Conseco, Inc. (NYSE:,CNO) announced that Todd M. ... senior vice president and treasurer. He will report to ... Hacker joins Conseco from YRC Worldwide, where he was ... treasurer from,2004-2005. From 2005-2006, he was senior vice president, ...
Cached Medicine News:Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 2Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 3Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 4Health News:FDA Approves Cialis(R) (tadalafil) for Once Daily Use for the Treatment of Erectile Dysfunction 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 2Health News:Irell & Manella Posts Strong Year for Corporate Transactions 3Health News:Irell & Manella Posts Strong Year for Corporate Transactions 4Health News:Irell & Manella Posts Strong Year for Corporate Transactions 5Health News:Irell & Manella Posts Strong Year for Corporate Transactions 6Health News:American Red Cross Announces New Leader for Biomedical Services 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: